Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.
You may also be interested in...
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.